Todays Report: Today, Eli Lilly and Co. (LLY) Lowered by Atlantic Securities

Today, Eli Lilly and Co. (LLY) Lowered by Atlantic Securities

Eli Lilly and Co. (NYSE:LLY) was downgraded by equities researchers at Atlantic Securities from an “overweight” rating to a “neutral” rating in a report issued on Friday, The Fly reports.

Other equities research analysts have also issued reports about the company. BMO Capital Markets lowered Eli Lilly and from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Citigroup Inc. reissued a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, November 8th. Jefferies Group reissued a “buy” rating and set a $100.00 price target (down from $105.00) on shares of Eli Lilly and in a research note on Friday, October 28th. Societe Generale reissued a “hold” rating and set a $78.00 price target on shares of Eli Lilly and in a research note on Thursday, October 27th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research note on Wednesday, October 26th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Eli Lilly and has an average rating of “Buy” and an average target price of $95.39.

Shares of Eli Lilly and (NYSE:LLY) opened at 68.00 on Friday. The company has a market capitalization of $71.92 billion, a P/E ratio of 29.58 and a beta of 0.28. The firm has a 50-day moving average price of $77.17 and a 200 day moving average price of $77.97. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $88.16.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by $0.08. The company earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. Eli Lilly and’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.89 earnings per share. On average, equities research analysts predict that Eli Lilly and will post $3.55 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be given a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a yield of 3.00%. Eli Lilly and’s dividend payout ratio is currently 88.70%.

In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of Eli Lilly and stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the sale, the insider now owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. Ronna Sue Cohen boosted its stake in shares of Eli Lilly and by 0.3% in the third quarter. Ronna Sue Cohen now owns 2,722 shares of the company’s stock worth $218,000 after buying an additional 9 shares in the last quarter. Tarbox Group Inc. boosted its position in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the period. Argent Trust Co boosted its position in shares of Eli Lilly and by 0.3% in the second quarter. Argent Trust Co now owns 4,184 shares of the company’s stock valued at $329,000 after buying an additional 12 shares during the period. First Citizens Bank & Trust Co. boosted its position in shares of Eli Lilly and by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock valued at $476,000 after buying an additional 18 shares during the period. Finally, Strategic Financial Group LLC boosted its position in shares of Eli Lilly and by 0.5% in the third quarter. Strategic Financial Group LLC now owns 3,449 shares of the company’s stock valued at $277,000 after buying an additional 18 shares during the period. 75.11% of the stock is owned by institutional investors.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Related posts

Leave a Comment